Episode Details
Back to EpisodesAcalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT
Season 8
Published 1 year, 8 months ago
Description
In this week's episode we’ll discuss the safety and efficacy of acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; learn more about alternative donor transplantation for severe aplastic anemia and discuss clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.
Featured Articles:
- Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial
- Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
- Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation